



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2523032 A1 2007/04/07

(21) **2 523 032**

**(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) A1

(22) Date de dépôt/Filing Date: 2005/10/07

(41) Mise à la disp. pub./Open to Public Insp.: 2007/04/07

(51) Cl.Int./Int.Cl. **A61K 39/00** (2006.01),
A61K 9/127 (2006.01), **A61P 35/00** (2006.01)

(71) Demandeur/Applicant:
IMMUNOVACCINE TECHNOLOGIES INC., CA

(72) Inventeurs/Inventors:
BROWN, ROBERT, CA;
MANSOUR, MARC, CA;
POHAJDAK, BILL, CA;
DAFTARIAN, PIROUZ, CA

(74) Agent: SMART & BIGGAR

(54) Titre : VACCINS POUR LA THERAPIE DU CANCER

(54) Title: VACCINES FOR CANCER THERAPY



Vaccines for Cancer Therapy

Applicant: ImmunoVaccine Technologies Inc.
1819 Granville Street
Halifax, Nova Scotia, Canada
B3J 3R1

Inventors: Robert BROWN
Marc MANSOUR
Bill POHAJDAK
Pirouz DAFTARIAN

all c/o ImmunoVaccine Technologies Inc., 1819 Granville Street, Halifax,
Nova Scotia, Canada, B3J 3R1

Description of the Invention

The invention provides compositions, particularly vaccine compositions that are useful for the prevention and treatment of cancer. The vaccine may be a vaccine composition as described in US Patent No. 6,793,923, a copy of which is attached hereto and which forms part of this application. Therapeutic treatment of cancer is described in the attached Appendix, which also forms part of this application. Treatment of cancer as described in the Appendix is merely exemplary. The invention is not limited to treatment or prevention of any particular type of cancer or any particular mode of administration of a vaccine.

Accordingly, in one aspect, the invention provides a method for preventing or treating cancer, comprising: administering to a subject in need thereof an effective amount of a vaccine composition, said vaccine composition comprising: a carrier comprising a continuous phase of a hydrophobic substance, liposomes, an antigen, and an adjuvant.

In another aspect, the invention provides a vaccine composition for preventing or treating cancer, the vaccine composition comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, an antigen, and an adjuvant.

The cancer may be any type of cancer, including, without limitation, cervical cancer, cancer caused by HPV, melanoma, breast cancer, or prostate cancer.

The antigen may be any antigen useful for the prevention or treatment of cancer and may be e.g. a multivalent antigen, recombinant antigen, synthetic antigen, or conjugated protein. A nonlimiting example is a synthetic antigen for cervical cancer, such as the fusion peptide of PADRE[pan-DR epitope] with a CTL epitope of E7 protein of human papilloma virus.

The adjuvant may be any suitable adjuvant, including, without limitation, a CpG oligonucleotide or a lipopeptide.

The subject is preferably a mammal, most preferably human.